Tailored therapy of patients with breast cancer - to avoid overtreatment as well as undertreatment - is dependent on the availability of prognostic and predictive biomarkers. Dr Jasmin Zeindler (University Hospital Basel, Switzerland) and colleagues presented two new prognostic biomarkers associated with survival: nectin-4 expression on triple-negative breast cancer cells and tumour infiltration by myeloperoxidase neutrophilic cells [1,2].
Triple-negative breast cancer represents about 10–20% of all invasive breast cancers and is associated with a poor prognosis. The nectin cell-adhesion protein 4 (nectin-4) is a junction protein involved in the formation and maintenance of cell junctions. Nectin-4 has previously shown to be expressed in about 60% of triple-negative breast cancer cells as well as in triple-negative breast cancer metastases, but to be absent in normal breast tissue, which makes it a potential specific target for triple-negative breast cance...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« What Is the Clinical Benefit of Treatment of Patients with Early Breast Cancer? Next Article
Over-active Bladder »
Table of Contents: BCC 2019
St. Gallen Consensus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.